Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

Operational risks are also reduced due to a lesser need for human intervention in hazardous environments, which is a very ...

The growing adoption of smart home technology is enabling consumers to both spot damage early and reduce its impact by ...

It’s become evident that a cloud-based IT portfolio brings organisations the greatest promise for providing the type of ...

These digitalisation initiatives could provide long-term benefits to the oil and gas industry, says GlobalData. GlobalData’s ...

This article was first published on GlobalData’s dedicated research platform, the Automotive Intelligence Center. "GlobalData ...

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

In a release sent to Rigzone recently, GlobalData said the oil and gas industry has seen a dip in active jobs in 2024 but ...

AI-driven adaptive cardiac devices are revolutionizing heart disease treatment by enabling real-time monitoring and dynamic ...

GlobalData predicts five technology trends to watch in 2025. AI remains the most talked about trend with a focus on Agentic AI going forward.

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.